Adma Biologics reiterates at least $530M 2026 revenue and raises minimum adjusted EBITDA to at least $275M as ASCENIV demand accelerates (NASDAQ:ADMA)
Adma Biologics (ADMA) reiterated its 2026 revenue target of at least $530M and raised its adjusted EBITDA minimum to $275M, citing accelerating demand for its ASCENIV product. CEO Adam Grossman attributed the growth to commercial momentum. The company reported these updates during its Q3 2026 earnings call.
How this was made
The 30-second read
Why it matters
The guidance raise suggests stronger commercial execution, which could drive short-term price appreciation.
Market read
First report of updated 2026 guidance for ADMA, indicating accelerated demand and higher earnings expectations.
What to watch
Potential regulatory or reimbursement hurdles for ASCENIV could temper growth.
Background
ADMA Biologics provides a specialty drug platform; ASCENIV is its lead product.
Ticker impact
ADMA Biologics reiterated 2026 revenue of at least $530M and raised minimum adjusted EBITDA to at least $275M as ASCENIV demand accelerates.
potential upside as the market prices in higher revenue and earnings expectations
The new revenue and EBITDA targets are materially higher than prior guidance, indicating accelerating demand for ASCENIV.
Market effects
Biotech sector may see broader optimism for companies with accelerating drug demand.
U.S. biotech stocks could benefit from the guidance lift.
Limited to investors tracking ADMA and similar biotech firms.
Counterpoint
If ASCENIV demand stalls, the guidance may be overly optimistic.
Key entities
- CompanyADMA Biologics
Biopharmaceutical company developing ASCENIV.
